CAS 957054-30-7
:Pictilisib
- 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine
- 2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)thieno[3,2-d]pyrimidine
- 4-[2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine
- Gdc 941
- Gdc-0941
- Gne 0941
- Pictilisib
- Thieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-
Pictilisib (GDC-0941)
CAS :Formule :C23H27N7O3S2Couleur et forme :Pale Yellow SolidMasse moléculaire :513.64Pictilisib
CAS :Pictilisib (GDC-0941) (GDC-0941) is a potent pan inhibitor of class I catalytic subunits of PI3K (IC50s: 3/33/3/75 nM for p110α/β/δ/γ).Formule :C23H27N7O3S2Degré de pureté :98.69% - 99.97%Couleur et forme :SolidMasse moléculaire :513.64GDC 0941
CAS :Pan-class I phosphatidylinositide 3-kinase (PI3K) inhibitor (IC50 = 3, 33, 3 and 75 nM at catalytic subunits p110α, p110β, p110δ and p110γ respectively). Inhibits proliferation in several cancer cell lines, such as glioblastoma, breast and prostate cancer cells. Has synergistic anti-cancer effect in combination with MEK/ERK kinase inhibitor GDC-0973 (cobimetinib).
Formule :C23H27N7O3S2Degré de pureté :Min. 95%Couleur et forme :White PowderMasse moléculaire :513.64 g/molGDC-0941
CAS :Produit contrôléApplications GDC-0941 is a potent and selective oral inhibitor of the class I PI3K. GDC-0941 demonstrated broad spectrum of activity in breast, ovarian, lung, and prostate cancer models. Studies has also shown GDC-0941 may enhance anti-tumor activity of Docetaxel (D494420) in human breast cancer models. Potent PI3K inhibitor.
References Jeffrey J.W., et al.: Clinical. Cancer. Rsch., 10, 1078 (2012); Murray, J.M., et al.: J. Medn. Chem., 55, 7686 (2012);Formule :C23H27N7O3S2Couleur et forme :NeatMasse moléculaire :513.64





